24th Oct 2006 07:02
Hikma Pharmaceuticals Plc24 October 2006 Hikma Pharmaceuticals - Trading update LONDON, 24 October 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), themultinational pharmaceuticals group, is today updating the market on the Group'scurrent trading performance. Our Branded and Injectables businesses continue to perform well and it isexpected that both will deliver strong growth for the full year. However, in theGeneric business we have seen decreasing wholesaler inventories and a lower thanforecast contribution from new product launches. It is therefore now expectedthat full year Generic sales will be slightly below those achieved in 2005. The Group will issue a further update prior to entering its close period inJanuary 2007. - ENDS -Enquiries: Hikma Pharmaceuticals PLCSusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals